ArticleTransfusion2020
No evidence of SARS-CoV-2 RNA among blood donors: A multicenter study in Hubei, China.
Article in Transfusion, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection.The Journal of clinical investigation · 2021Trial
- SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network.Blood transfusion = Trasfusione del sangue · 2022Article
- Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry.Vox sanguinis · 2022Review
- Views and Attitudes of Blood Donors toward Blood Donation during the COVID-19 Pandemic in Thrace Region, Greece.International journal of environmental research and public health · 2022Article
- Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Review
- The Impact of COVID-19 on Blood Transfusion Services: A Systematic Review and Meta-Analysis.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021Article
- Impact of COVID-19 and lockdown regarding blood transfusion.Transfusion · 2021Article
- Analysis of current SARS-CoV-2 infection in a large population of blood donors evidenced that RNAemia is rare in plasma.Transfusion · 2021Article
- Absence of SARS-CoV-2 viraemia in a blood donor with COVID-19 post-donation.Transfusion medicine (Oxford, England) · 2021Article
- Comparison of Digital PCR and Quantitative PCR with Various SARS-CoV-2 Primer-Probe Sets.Journal of microbiology and biotechnology · 2021Article
- Comparison of Seven Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid Detection Reagents with Pseudovirus as Quality Control Material.The Journal of molecular diagnostics : JMD · 2021Article
- Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China.Journal of medical virology · 2021Article
- Severe acute respiratory syndrome coronavirus-2: implications for blood safety and sufficiency.Vox sanguinis · 2021Review
- The Impact of COVID-19 Pandemic on Blood Transfusion Services: A Perspective from Health Professionals and Donors.Journal of multidisciplinary healthcare · 2021Article
- Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama.Frontiers in medicine · 2021Article
- Modelling RT-qPCR cycle-threshold using digital PCR data for implementing SARS-CoV-2 viral load studies.PloS one · 2021Article
- No evidence of SARS-CoV-2 RNA among blood donors: A multicenter study in Hubei, China.Transfusion · 2020Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA could be detected in the blood of infected cases. From February 9, all blood establishments in Hubei province, China, implemented nucleic acid testing (NAT) for SARS-CoV-2 RNA among blood donors to ensure blood safety. STUDY DESIGN AND
methodsNucleic acid test screening individually (ID) or by minipool (MP) testing was performed according to the manufacturer's instructions. Inactivated culture supernatant of SARS-CoV-2-infected Vero cells was quantified by droplet digital polymerase chain reaction (ddPCR) and series diluted with negative plasma to evaluate the assay's performance.
resultsThe limit of detection of the kit for MP testing was 62.94 and 33.14 copies/mL for N and ORF1ab region, respectively. ID testing could achieve 3.87 and 4.85 copies/mL for two regions using 1600 μL of plasma. Coefficients of variations of two different concentrations of reference samples were all less than 5% in MP testing. As of April 30, 2020, a total of 98,342 blood donations including 87,095 whole blood donations and 11,247 platelet donations were tested by ID or MP testing, and no RNAemia was found. In addition, Hubei province suffered precipitously decreased blood supply, especially in February: 86% reduction compared with the same period of 2019.
conclusionNucleic acid test screening of SARS-CoV-2 on blood donations is suitable in blood establishments using the commercial real-time PCR detection kit based on available instruments. The negative result indicated that SARS-CoV-2 appears to be no direct threat to blood safety but raises some serious issues for general blood supply.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.